Business context and reporting period
Filing identity: The supplied filing is Gemini Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2021—not a filing by Disc Medicine, Inc. Confirm the issuer before relying on this summary. Gemini is a clinical-stage biotechnology company developing treatments for genetically defined age-related macular degeneration (AMD). Its lead candidate, GEM103, was in Phase 2a development; it had no approved products or product revenue.
On February 5, 2021, Gemini completed a business combination with FS Development Corporation and a concurrent PIPE financing. The transaction generated approximately $195.9 million in net proceeds and was accounted for as a reverse recapitalization.
Financial performance and liquidity
Amounts below are in U.S. dollars; financial-statement amounts are reported in thousands unless noted.
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.8 million | $8.2 million |
| General and administrative expense | $4.7 million | $1.4 million |
| Total operating expenses / operating loss | $16.5 million | $9.6 million |
| Net loss | $19.0 million | $9.7 million |
| Net loss per share, basic and diluted | $0.59 | $0.67 |
| Cash used in operating activities | $15.0 million | $9.9 million |
| Cash provided by financing activities | $195.5 million | $20.1 million |
At March 31, 2021, cash and cash equivalents were $185.0 million, total assets were $189.4 million, and stockholders’ equity was $171.2 million. Current assets were $188.6 million versus current liabilities of $13.8 million. The company reported an accumulated deficit of $131.9 million. No revenue or profit margin was reported; margins are not meaningful without revenue.
Term-loan principal outstanding was approximately $9.2 million, including $5.0 million classified as current. The loan’s floating rate was reported as 1.75% at quarter-end, with maturity on January 1, 2023. Management said cash resources were expected to fund operating expenses and capital requirements into 2023, subject to estimates and risks.
Material changes versus the prior comparable period
- Operating expenses increased $6.9 million year over year. R&D expense rose $3.6 million, primarily due to GEM103 clinical-trial activity and higher R&D staffing. G&A expense rose $3.3 million, reflecting personnel and stock-based compensation, public-company costs, and professional fees.
- Net loss increased $9.3 million. Interest expense increased by $1.7 million, largely due to accretion of the convertible-note discount; the quarter also included a $0.7 million loss on conversion of those notes.
- Cash increased substantially following the business combination and PIPE. Financing cash flow was $195.5 million, compared with $20.1 million in Q1 2020.
- Weighted-average shares increased to 32.0 million from 14.5 million, reflecting the transaction and recapitalization. The reported loss per share nevertheless declined to $0.59 from $0.67.
Outlook, commentary, risks, and unusual items
- Management expected losses and expenses to continue and R&D and G&A spending to increase as clinical programs advance and the company operates as a public company. Additional financing may be needed; the filing does not provide specific financial guidance beyond the estimated cash runway into 2023.
- COVID-19 had no significant effect on Q1 2021 financial results, according to management, but could disrupt trial enrollment, retention, data collection, trial timelines, and supplies from contract manufacturers and research organizations.
- Management identified substantial drug-development, regulatory, manufacturing, intellectual-property, competition, and financing risks. If funding is unavailable, Gemini may have to delay, reduce, or stop development activities or seek unfavorable collaborations.
- The $14.0 million convertible notes, plus accrued interest, converted into Series B preferred shares immediately before the business combination; the conversion generated a $0.7 million accounting loss. The business combination and PIPE produced approximately $195.9 million in net proceeds. PIPE investors purchased 9.506 million shares at $10 per share.
- Potential license-related milestone payments and royalties were disclosed, but no liabilities were recorded for contingent amounts where milestones were not considered probable. The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm that Gemini Therapeutics, Inc.—rather than Disc Medicine, Inc.—is the intended issuer and that the ticker and filing correspond to the investment under review.
- Review subsequent filings for actual cash burn, financing activity, and any change to management’s estimated runway into 2023.
- Check current GEM103 trial status, timelines, enrollment, and results, including any effects of COVID-19 on data quality or study completion.
- Verify current term-loan balance, repayment schedule, covenants, and interest-rate exposure.
- Assess dilution from shares issued in the business combination and PIPE, outstanding equity awards, and potential future financing.